Pepinemab – Anti-SEMA4D Antibody for Neurodegenerative Disease and Cancer Immunotherapy

VACCINEX

Unique Targets
Novel Mechanisms
New Medicines

Corporate Presentation

January 2022

VCNX

Forward Looking Statements

To the extent that statements contained in this presentation are not descriptions of historical facts regarding Vaccinex, Inc. ("Vaccinex," "we," "us," or "our"), they are forward-looking statements reflecting management's current beliefs and expectations. Such statements include, but are not limited to, statements about the Company's plans, expectations and objectives with respect to the results and timing of clinical trials of pepinemab in various indications, the use and potential benefits of pepinemab in Huntington's and Alzheimer's disease and other indications, and other statements identified by words such as "may," "will," "appears," "expect," "planned," "anticipate," "estimate," "intend," "hypothesis," "potential," "advance," and similar expressions or their negatives (as well as other words and expressions referencing future events, conditions, or circumstances). Forward-looking statements involve substantial risks and uncertainties that could cause the outcome of the Company's research and pre-clinical development programs, clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties inherent in the execution, cost and completion of preclinical and clinical trials, uncertainties related to regulatory approval, the risks related to the Company's dependence on its lead product candidate pepinemab, the ability to leverage its ActivMAb® platform, the impact of the COVID-19 pandemic, and other matters that could affect the Company's development plans or the commercial potential of its product candidates. Except as required by law, the Company assumes no obligation to update these forward-looking statements. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled "Risk Factors" in the Company's periodic reports filed with the Securities and Exchange Commission ("SEC") and the other risks and uncertainties described in the Company's most recent year end Annual Report on Form 10-K and subsequent filings with the SEC.

NOVEL ANTIBODY THERAPEUTICS TO TARGET UNMET NEEDS

- ✓ **Novel Mechanistic Approach**
  Lead product: Pepinemab
  First in class: Blocks a unique target, Semaphorin 4D
  Humanized IgG4 monoclonal antibody,

- ✓ **Clinical Proof of Concept**
- ✓ **Advanced clinical programs with near-term opportunities for monetization by partnering**

Pepinemab
SEMA4D pathways are activated
in immune and central nervous systems in response to stress/disease

Cancer Immunology

- ❖ Facilitates infiltration of T cells and reduce immunosuppression to potentially overcome immune resistance
- ❖ Data suggest pepinemab may complement immune checkpoint therapies without added toxicity
- ❖ Ongoing Phase 1/2 trial in head and neck cancer, partnered with Merck

Neurodegenerative Disease

- ❖ Targets underlying disease pathology
- ❖ Data suggest ability to repair and restore normal functions
- ❖ Broad application
- ❖ Phase 3-ready asset in Huntington's Disease
- ❖ Ongoing Phase 1/2 trial in Alzheimer's Disease

PIPELINE and MILESTONES

Research/Preclinical	Phase 1	Phase 2	Phase 3	Partner/Funding	Milestone
Pepinemab Antibody Platform (anti-Semaphorin 4D Mab)					
Oncology					
Pepinemab COMBO with Avelumab in **Non Small Cell Lung Cancer**			CLASSICAL-Lung	Merck, KGaA Darmstadt	Complete, Published 2021
Pepinemab COMBO with Pembrolizumab in **Head and Neck Cancer**			KEYNOTE B84	Merck, MSD	Ongoing **Data H2 2022**
Neurology					
Pepinemab in **Huntington's Disease** (Orphan Drug and Fast Track Designations)			SIGNAL		Complete, **Publish H2 2022**
Pepinemab in **Alzheimer's Disease**			SIGNAL-AD	alzheimer's association; Alzheimer's Drug Discovery Foundation	Ongoing **Data H1 2023**

All Studies Sponsored by: VACCINEX

PEPINEMAB IMMUNO-ONCOLOGY

Novel mechanism of action

Neutralizes the SEMA4D barrier at tumor boundary and inhibits immune suppressor cells to facilitate anti-tumor immune cells

→ Data suggests synergy with immune checkpoint therapy

Well tolerated

STATUS		SUMMARY
Phase 1b/2 Non Small Cell Lung Cancer (NSCLC) **Complete** Data published in Clinical Cancer Research, 2021 Pepinemab Combination with Bavencio ™	Sponsored by: VACCINEX Co-funded by: EMD Serono/Merck KGaA, Darmstadt MERCK	**CLASSICAL-Lung** • Well tolerated • Anti-tumor activity observed in some patients with challenging PD-L1 negative or low tumors • Anti-tumor activity observed in some patients whose cancer was resistant to prior therapy with single-agent checkpoint inhibitors • Increased penetration of cytotoxic T cells following treatment
Phase 1b/2 Head and Neck Cancer (R/M HNSCC) Initiated Q2 2021 **Data expected 2H 2022** Pepinemab Combination with Keytruda ™	Sponsored by: VACCINEX Drug provided by: Merck, MSD MERCK	**Head and Neck Cancer (Keynote B84)** • RATIONALE: High levels of myeloid derived suppressor cells (MDSC) are induced by SEMA4D and are a source of resistance to immune checkpoint therapy • First line treatment for recurrent or metastatic HNSCC, n=62 • 19 sites, US • Safety Run-In: Complete

PEPINEMAB
NEURODEGENERATIVE DISEASE

Unique Mechanism of Action:

We believe Pepinemab has the potential to block chronic glial activation and restore their normal support functions.

Broadly applicable approach:

Does not target disease-specific insult, instead targets common trigger of reactive inflammation which contributes to and amplifies neurodegeneration

STATUS		SUMMARY
Phase 2 Huntington's Disease Double-blind, Placebo-controlled **Complete**	Sponsored by: VACCINEX Granted Orphan Disease and Fast Track Designations by FDA	**Huntington's Disease (SIGNAL)** • Well tolerated • Co-primary endpoints did not achieve statistical significance (CGIC and family of 2 cognitive assessments) • Improvements observed in cognitive assessments • Observed reduced brain atrophy (vMRI) and restored loss of metabolic activity (FDG-PET) • *Phase 3-ready asset*
Phase 1/2a Alzheimer's Disease Double-blind, Placebo-controlled Initiated Q2 2021 **Data expected H1 2023**	Sponsored by: VACCINEX Funding by: alzheimer's association, Alzheimer's Drug Discovery Foundation	**Alzheimer's Disease (SIGNAL-AD)** • Primary endpoint: Safety • Key efficacy assessments: Cognition and metabolic activity (FDG-PET) • 14 sites, US • 40 participants (n=20/treatment arm)
Currently exploring pharma collaboration		

ActivMab Discovery Solutions

Antibody Library

Diverse Antibody Library (10^10) Screened as Human IgG in Mammalian Cells



Antigen Virus

Virions expressing Complex Membrane Proteins for Antibody Discovery



ActivMAb Technology

Discovery Solutions

Target Identification

Large cDNA library expressed in Mammalian Cells



Protein Optimization

Mammalian expression of mutant libraries to enhance expression



Poxvirus based antibody and protein engineering solutions

Unique capability for selection of high value antibodies against hard-to-target multi-pass membrane receptors
(i.e. GPCRs, ion channels)

Designed as a sustainable engine for value creation through pipeline expansion and strategic collaborations

Active collaborations with two major pharma and multiple biotech partners



Pepinemab Antibody for Cancer Immunotherapy

■ Unique Targets ■ Novel Mechanisms ■ New Medicines

PROPOSED MECHANISM OF ACTION:

Preclinical and clinical evidence suggests pepinemab may reprogram underlying pathology in cancer



WHY DOES IMMUNE RESPONSE FAIL IN TUMORS?

Immune Exclusion

Activated T-cells and dendritic cells can't penetrate tumor

Sema4D is expressed at tumor margin



Tumor SEMA4D

Sema4D binds PLXN receptors on DCs and restricts penetration



Tumor Dendritic Cells (CD11c)

T-cells are excluded from tumor



Tumor CD8+ CD4+ T Cells

Pro-inflammatory cells are excluded from tumor and build up at the invasive edge

CD8 T cells align with Sema4D at the invasive edge of the tumor. Most of these excluded T-cells express Sema4D. Dendritic Cells express receptors for SEMA4D and are heavily excluded at the invasive edge.

Human metastatic colorectal tumor, in collaboration with Emory University (NCT03373188)

IMMUNE BALANCE IN TUMOR MICROENVIRONMENT

Pepinemab:

1. ↑ cytotoxic T cells
2. ↓ inhibitory suppressor cells

No treatment
Low CD8+ T cells
High Tumor content and MDSC



Myeloid Derived Suppressor Cells (MDSC)

Pepinemab
High CD8+ T cells
Low tumor content and MDSC



Tumor CD8+ T cells

Biopsies from patients with metastatic MSS Colorectal Cancer

Human metastatic colorectal tumor, in collaboration with Winship Cancer Institute, Emory University integrated biomarker study (NCT03373188), Wu et al. Ann Surg Oncol. 2021

UNIQUE MECHANISM

Preclinical data suggests that pepinemab complements other immunotherapies

Pepinemab
Facilitates T-cell infiltration
Reduces immune suppression

Immune Checkpoint Inhibitors
Sustain T-cell activity

Combination therapy to overcome multiple immune resistance mechanisms

Combination therapy: Preclinical Data

HNSCC tumor model (MOC1)



Data suggest that pepinemab complements other immune-activating therapies, including

anti-PD1/L1, anti-CTLA-4, anti-LAG3, anti-TGF-β, DC vaccine, etc

CLINICAL POC

Phase 1b/2 CLASSICAL-Lung

July 1, 2021 | Volume 27 | Number 13

CLINICAL CANCER RESEARCH
HIGHLIGHTS
Selected Articles from This Issue

A Phase Ib/2 Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer AC

Michael Rahman Shafique[1], Terrence Lee Fisher[2], Elizabeth E. Evans[2], John E. Leonard[2], Desa Rae Electa Pastore[2], Crystal L. Mallow[2], Ernest Smith[2], Vikas Mishra[2], Andreas Schröder[3], Kevin M. Chin[4], Joseph Thaddeus Beck[5], Megan Ann Baumgart[6], Ramaswamy Govindan[7], Nashat Y. Gabrail[8], Alexander I. Spira[9], Nagashree Seetharamu[10], Yanyan Lou[11], Aaron Scott Mansfield[12], Rachel E. Sanborn[13], Jonathan W. Goldman[14], and Maurice Zauderer[2]

Sponsored by: VACCINEX
Co-funded by: MERCK

1. **Well tolerated.** Pepinemab does not appear to increase immune-related toxicities of partner drug, but data suggests increased penetration of cytotoxic T cells.
2. **Unmet Need: PD-L1 low/negative tumors**
   - Reported single agent anti-PDx: **ORR ~10-15%**
   - Combination with pepinemab: **ORR 25-33%**
3. **Unmet Need:** Antitumor activity observed in immune checkpoint resistant/refractory tumors



RATIONALE FOR TREATMENT OF HNSCC

Head and Neck cancer (HNSCC)

- Data suggest that SEMA4D is strongly expressed in HNSCC & induces high levels of myeloid derived suppressor cells (MDSC)
- Relatively low (17-19%) response rate to immune checkpoint therapy in HNSCC

Hypothesis: Inhibiting MDSC with pepinemab may enhance response to pembrolizumab in HNSCC





Head and Neck Cancer Trial

- All patients receive standard of care Keytruda®, plus Pepinemab for first-line treatment

➢ Safety Phase: **complete**
➢ 19 sites planned, USA

- Potential COVID-related delays
  - Mitigate by increased communication and providing sites with patient recruitment materials

Keynote B84: Pepinemab + Keytruda® for first-line treatment of recurrent or metastatic head and neck cancer



PEPINEMAB FOR IMMUNO-ONCOLOGY SUMMARY & NEXT STEPS

Mechanism of Action

Preclinical data suggest:
Facilitate infiltration of T cells and dendritic cells

Reduce immunosuppression

Safety and Tolerability

Well tolerated

Does not appear to enhance immune-related toxicities of partner drug

Observed Clinical Activity

Reprogram immune infiltrate in TME

Potential to overcome immune resistance in
PD-L1 negative/low tumors
and ICI resistant/refractory tumors

Ongoing Phase 2 trial in R/M HNSCC
Broad application in solid tumors

VACCINEX

Pepinemab Antibody for treatment of Neurodegenerative Disease

■ Unique Targets ■ Novel Mechanisms ■ New Medicines

PROPOSED MECHANISM OF ACTION:

Preclinical and clinical evidence suggests pepinemab may reprogram underlying pathology in CNS diseases



SEMA4D IS OBSERVED TO BE UPREGULATED IN NEURONS DURING UNDERLYING DISEASE PROGRESSION



Human autopsy sections of frontal lobe

HUNTINGTON'S DISEASE

Genetic Disease
HD is caused by dominant mutation in a single gene.

Unmet need
No approved treatments to alter the course of Huntington's Disease.

~40,000 individuals
with manifest disease in US

>150,000 more
at risk of inheriting mutation



Symptoms
Cognitive impairment = most significant impact on daily life (FDA Voice of the Patient)



Photo credit: Huntington Society of Canada

HUNTINGTON'S DISEASE

Abbreviated Clinical Trial Design

SIGNAL

Orphan Disease and Fast Track Designations



ABBREVIATED SAFETY AND BASELINE CHARACTERISTICS

mITT: Early Manifest HD

Pepinemab (PEPI) SEMA4D blocking antibody is well tolerated

Early Manifest HD	Placebo (n=88)	Pepinemab (n=91)
Discontinued Treatment Early	10	13
Had any SAE (*)	8	4
Had any Grade 3+ AE (*)	14	17
CAG repeat length	44.1	43.5
CAP score**	470	466
UHDRS-DCL at screening DCL-4, Unequivocal HD (>99% confident)	88 (100%)	91 (100%)
UHDRS-TFC at screening, n (%)		
11 12-13	33 (38%) 55 (62%)	29 (32%) 61 (68%)
MoCA score, mean (SE)	26.02 (2.04)	26.14 (2.30)
MoCA <26 subgroup	23.97 (0.94)	23.78 (1.07)
MoCA ≥26 subgroup	27.44 (1.21)	27.72 (1.34)

*pre-COVID era;
**CAP score = age × (CAG repeat length – 33.66)

COGNITIVE ASSESSMENT BATTERY (HD-CAB)

mITT Co-Primary and pre-specified Exploratory analysis

HD-CAB Composite Index of 6 Cognitive Assessments



HD-CAB Composite Index: Pre-specified Exploratory

LS Mean Difference Estimate (95% CI)	One-sided p-value	Favors Pepinemab	Critical value
0.13 (0.03, 0.23)	**0.007**	**Yes**	**Yes [0.025]**

Two-item HD Cognitive Assessment: Pre-specified Co-Primary

LS Mean Difference Estimate (95% CI)	One-sided p-value	Favors Pepinemab	Critical value
OTS: -1.98 (-4.00, 0.05)	**0.028**	**Yes**	**No [0.025]**
PTAP: 1.43 (-0.37, 3.23)	**0.060**		

PEPINEMAB APPEARS TO REDUCE BRAIN ATROPHY

Volumetric MRI– Boundary Shift Integral Analysis (BSI)
Pre-specified Exploratory Endpoint

CBSI (caudate atrophy)



LS Mean Difference Estimate (95% CI):
CBSI: -1.54 (-2.79, -0.29);
p = 0.017

VBSI (ventricular expansion)



VBSI:-2.47 (-5.04, 0.10);
p = 0.060

FDG-PET CORRELATES WITH COGNITIVE FUNCTION

Pre-specified Exploratory Endpoint

FDG-PET measures brain metabolic activity.

Decline in FDG-PET is reported to correlate with cognitive impairment in neurodegenerative diseases.

Pepinemab treatment appears to reverse loss of metabolic activity.

Change in FDG-PET at Month18



Difference (PEPI-PBO) at Month 18



SUVR = standardized uptake value ratio

SIGNAL Phase 2 Trial
Summary, Lessons Learned, Next Steps

Orphan Disease and Fast Track Designations




Proposed Mechanism of Action	Safety and Tolerability	Clinical Activity	Target Engagement
Preclinical data suggests reduced neuroinflammation and restoration of normal glia function	**Well tolerated** Intravenous administration	Prespecified primary endpoints were not significant Evidence suggests potential cognitive benefit: HD-CAB, Apathy, FDG-PET Greatest benefit from treatment was detected in patients with signs of mildly advanced disease Reduced brain atrophy observed	Confirmed penetration into CNS at expected level Antigen-antibody complexes detected

Continued clinical development in Huntington's Disease
Initiated phase 1/2a trial in Alzheimer's Disease

Alzheimer's Disease Trial

- Participants receive Pepi OR Placebo

➢ Safety Phase: 3/4 enrolled
➢ 10/14 sites **open**

- Protocol and COVID-related delays
  - amend inclusion criteria
  - increased communication and provided sites with patient recruitment materials
- Double-blind, placebo-controlled study

SIGNAL-AD

Phase 1b: Safety

- Total of 4 participants

Phase 2: Expansion Phase

- Placebo
- Pepinemab
- Total of 40 participants

JUL 2021 — **Q1, 2022** — **H1 2023**

Safety Period

Data Safety Monitoring Board meeting

Topline Data

Cognitive Function measures:
CDR-SB, ADAS-Cog13, MMSE, CDRS

Brain imaging:
FDG-PET
MRI

VACCINEX

alzheimer's association

Alzheimer's Drug Discovery Foundation

PIPELINE and MILESTONES

Research/Preclinical	Phase 1	Phase 2	Phase 3	Partner/Funding	Milestone
Pepinemab Antibody Platform (anti-Semaphorin 4D Mab)					
Oncology					
Pepinemab COMBO with Avelumab in **Non Small Cell Lung Cancer**			CLASSICAL-Lung	Merck, KGaA Darmstadt	Complete, Published 2021
Pepinemab COMBO with Pembrolizumab in **Head and Neck Cancer**			KEYNOTE B84	Merck, MSD	Ongoing **Data H2 2022**
Neurology					
Pepinemab in **Huntington's Disease** (Orphan Drug and Fast Track Designations)			SIGNAL		Complete, **Publish H1 2022**
Pepinemab in **Alzheimer's Disease**			SIGNAL-AD	alzheimer's association, Alzheimer's Drug Discovery Foundation	Ongoing **Data Q1 2023**

All Studies Sponsored by: VACCINEX

ACHIEVEMENTS AND MILESTONES

Publish Clinical Data for SIGNAL study in Huntington's Disease	**H1 2022**
Publish Preclinical Data in Rett Syndrome, an orphan disease	August, 2021
Publish Clinical Data for Pepinemab in Combination with Avelumab in NSCLC Clinical Cancer Research, https://clincancerres.aacrjournals.org/content/27/13/3505	April, 2021
Enrollment of first patient for phase 2 study of Pepinemab in Combination with Keytruda® in front line Head & Neck Cancer **Expect interim data**	Q2 2021 **H2-2022**
Enrollment of first patient in Alzheimer's disease phase 1b/2a study **Expect topline data from randomized, double-blind, placebo-controlled study**	Q2 2021 **H1 2023**

Currently exploring pharma collaborations

Vaccinex, Inc. (Nasdaq: VCNX) is a publicly traded clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases with unmet medical needs, including cancer and neurodegenerative diseases.

INCORPORATED
2001

HEADQUARTERS
Rochester, NY

EMPLOYEES
39

IPO NASDAQ VCNX
August 2018

FEBUARY 2021 CAPITAL RAISE
$32 M

CASH BALANCE*
$13.8 M

SHARES OUTSTANDING*
$30.8 M

ANALYSTS
BTIG (T.Shrader)

*as of 30SEP2021

Vaccinex Leadership Team

Maurice Zauderer, Ph.D.	**Founder, President and Chief Executive Officer**. Formerly, Professor at University of Rochester and at Columbia University.
Scott E. Royer, CFA, MBA	**Chief Financial Officer**. Formerly, Chief Financial Officer and Director of Finance of the Medical Films Group of Carestream Health, a medical and dental imaging company and an independent subsidiary of Onex Corporation, a Canadian publicly traded private equity investment firm. Mr. Royer earned an Executive MBA from Villanova University, and is a credentialed Chartered Financial Analyst (CFA)
Ernest S. Smith, Ph.D.	**Chief Scientific Officer and Senior Vice President, Research**. Dr. Smith received a Ph.D. in Immunology from the University of Rochester. Dr. Smith has held several leadership roles at Vaccinex since 2001 and holds several patents, including ActivMab® technology and Semaphorin 4D/pepinemab.
Elizabeth E. Evans, Ph.D.	**Chief Operating Officer and Senior Vice President, Discovery and Translational Medicine**. Dr. Evans received an M.S. in Immunology and a Ph.D. in Pathology from the University of Rochester. Dr. Evans has held several leadership roles at Vaccinex since 2001 and holds several patents on SEMA4D/pepinemab.
John E. Leonard, Ph.D.	**Senior Vice President, Development**. Formerly Vice President, Program Executive of Biogen Idec, Inc., a publicly traded biotechnology company. Dr. Leonard received a Ph.D. in Biochemistry from the University of California, Riverside

Appendix

CONTACT US

Maurice Zauderer, PhD
President & CEO
mzauderer@vaccinex.com

Elizabeth Evans, PhD
COO
eevans@vaccinex.com

ActivMAb Technology

Ernest Smith, PhD
CSO
esmith@vaccinex.com

Vaccinex Scientific Advisors - Neurology

Eric Siemers, MD	President of Siemers Integration LLC. Distinguished medical fellow for Eli Lilly and Company's Alzheimer's Disease Global Development Team, founded and headed the Indiana University Movement Disorder Clinic. Served on the Board of Directors of the American Society of Experimental Neurotherapeutics, as founding member and Chair of the Alzheimer's Association Research Roundtable, and Steering Committee member for the Alzheimer's Disease Neuroimaging Initiative (ADNI).
Karl D. Kieburtz, MD, MPH	President of Clintrex LLC, providing services regarding research and regulatory strategy for therapeutic development of interventions for brain disorders. Chair of the FDA Peripheral and Central Nervous System Drugs Advisory Committee and sits on the American Academy of Neurology (AAN) Clinical Research Subcommittee, the International Executive Committee of the Movement Disorders Society (MDS), the Board of Directors for the American Society for Experimental Neuro Therapeutics(ASENT), and the Council of the American Neurological Association (ANA),chair of the FDA Peripheral and Central Nervous System Drugs Advisory Committee.
Ira Shoulson, MD	Dr. Shoulson is a long time leader in Huntington's disease research. From 2011 to July 2018, Dr Shoulson was Professor of Neurology, Pharmacology and Human Science and Director of the Program for Regulatory Science and Medicine (PRSM) at Georgetown University where he was principal investigator of the FDA-Georgetown University Collaborating Center of Excellence in Regulatory Science and Innovation. From 1990 to 2011, Dr Shoulson was the Louis C. Lasagna Professor of Experimental Therapeutics and Professor of Neurology, Pharmacology and Medicine at the University of Rochester School of Medicine & Dentistry in Rochester, New York. Dr. Shoulson is an elected member of the National Academy of Medicine of the National Academy of Sciences.
Ralf Reilmann, MD	Founding Director and C.E.O. of the George-Huntington-Institute, Dept. of Radiology at the University of Muenster and the Dept. of Neurodegeneration and Hertie Institute for Clinical Brain Research at the University of Tuebingen.

Vaccinex Scientific Advisors - HNSCC Clinical Advisory Board

Barbara Burtness, MD	Professor of Medicine (Medical Oncology) at Yale, leader of the Disease Aligned Research Team for the Head and Neck Cancers Program and Co-Leader of the Developmental Therapeutics Research Program at Yale Cancer Center. Chair of ECOG-ACRIN Head and Neck Therapeutics Committee, served on the NCCN and SITC Head and Neck Guidelines Committee, and the NCI Head and Neck Cancer Steering Committee. Co-chair of the NCI Clinical Trials Planning Meeting on TP53-Mutated Head and Neck Cancer and FDA Project 2025 for Head and Neck. Founding Director of the Yale Head and Neck Cancer SPORE and has led numerous clinical trials, including the international phase III trial which led to regulatory approval of immunotherapy in first-line treatment of head and neck cancer.
Robert Haddad, MD	Chief, Division of Head and Neck Oncology. McGraw Chair, Head and Neck Oncology, Dana-Farber Cancer Institute. Professor, Medicine, Harvard Medical School.
Douglas Adkins, MD	Professor, Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in St. Louis. NCI Head and Neck Steering Committee and Metastatic and Recurrent Head & Neck Cancer Task Force
Nabil Saba, MD	Director of the Head and Neck Cancer Medical Oncology Program at Winship Cancer Institute of Emory University, Professor and Vice Chair for Quality and Safety in the Department of Hematology and Medical Oncology and holds a joint appointment as Professor in the Department of Otolaryngology at Emory University School of Medicine. Chair of the National Cancer Institute's task force for recurrent metastatic head and neck cancer and Chair of the Rare Tumors Task Force of the National Cancer Institute's Head and Neck Cancer Steering Committee. Member of the NRG Oncology and Eastern Cooperative Oncology Group (ECOG) Head and Neck Cancer Core Committees, the ASCO clinical guidelines committee, and the ASCO Head and Neck Guideline Advisory Group.

Vaccinex Board of Directors

Albert D. Friedberg	Chairman, President and CEO of Friedberg Mercantile Group, a Toronto-based commodities and investment management firm he founded in 1971. He served as Chairman of the Toronto Futures Exchange from March 1985 to June 1988.
Chrystyna M. Bedrij	Co-Founder and Principal, Griffin Securities
Jacob B. Frieberg	Principal, The WTF Group.
J. Jeffrey Goater	CEO of Surface Oncology, Formerly, CFO of Voyager Therapeutics.
Bala S. Manian, Ph.D.	Founder (or co-founder) of Quantum Dot Corporation, SurroMed, Biometric Imaging, LumisysInc., Molecular Dynamics and ReaMetrix.
Gerald E. Van Strydonck	Formerly, Managing Partner at PricewaterhouseCoopers.
Barbara Yanni	Formerly, Vice President and Chief Licensing Officer at Merck & Co., Inc.
Maurice Zauderer, Ph.D.	Vaccinex Founder, President and Chief Executive Officer. Formerly, Professor at University of Rochester and at Columbia University.

Vaccinex Selected References, Oncology

1. Shafique MR, Fisher TL, Evans EE, Leonard JEE, Pastore DRE, Mallow CL, Smith E, Mishra V, Schroder A, Chin KA, Beck JT, Baumgart MA, Govindan R, Gabrial NY, Spira AI, Seetharamu N, Lou Y, Mansfield AS, Sanborn RE, Goldman JW, Zauderer M. **A Phase Ib/2 Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer**. Clin Cancer Res 2021, doi: 10.1158/1078-0432.CCR-20-4792
2. Clavijo PE, Friedman J, Robbins Y, Moore EC, Smith ES, Zauderer M, Evans EE, Allen CT. **Semaphorin4D inhibition improves response to immune checkpoint blockade via attenuation of MDSC recruitment and function**. Cancer Immunol Res. 2019 Feb;7(2):282-291
3. Evans EE, Jonason AS Jr, Bussler H, Torno S, Veeraraghavan J, Reilly C, Doherty MA, Seils J, Winter LA, Mallow C, Kirk R, Howell A, Giralico S, Scrivens M, Klimatcheva K, Fisher TL, Bowers WJ, Paris M, Smith ES, Zauderer M. **Antibody blockade of semaphorin 4D promotes immune infiltration into tumor and enhances response to other immunomodulatory therapies.** Cancer Immunol Res. 2015 Jun;3(6): 689-701. http://www.ncbi.nlm.nih.gov/pubmed/25614511
4. Amita Patnaik, Glen J. Weiss, John E. Leonard, Drew Warren Rasco, Jasgit C. Sachdev, Terrence L. Fisher, Christine Reilly, Laurie A. Winter, Robert B. Parker, Danielle Mutz, Lisa Blaydorn, Anthony W. Tolcher, Maurice Zauderer and Ramesh K. Ramanathan. **Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of VX15/2503, a Humanized IgG4 anti-SEMA4D Antibody, in a First-In-Human Phase 1 Study of Patients with Advanced Solid Disease.** Clin Cancer Res. 2015 Oct 7. http://clincancerres.aacrjournals.org/content/22/4/827.full.pdf+html
5. Leonard JE, Fisher TL2 Winter LA, Cornelius CA, Reilly C, Smith ES, Zauderer M. **Nonclinical Safety Evaluation of VX15/2503; a Humanized IgG4 Anti-SEMA4D Antibody.** Mol Cancer Ther. 2015 Feb 5 http://www.ncbi.nlm.nih.gov/pubmed/25657333
6. Fisher TL, Reilly CA, Winter LA, Pandina T, Jonason A, Scrivens M, Balch L, Bussler H, Torno S, Seils J, Mueller L, Huang H, Klimatcheva E, Howell A, Kirk R, Evans E, Paris M, Leonard JE, Smith ES, Zauderer M. **Generation and preclinical characterization of an antibody specific for SEMA4D**. Mabs. 2015 Oct 20. http://www.tandfonline.com/doi/abs/10.1080/19420862.2015.1102813
7. Fisher, T. L., J. Seils, C. Reilly, V. Litwin, L. Green, J. Salkowitz-Bokal, R. Walsh, S. Harville, J. E. Leonard, E. Smith, and M. Zauderer. 2016. **Saturation monitoring of VX15/2503, a novel semaphorin 4D-specific antibody, in clinical trials.** *Cytometry B Clin. Cytom.* 90: 199-208. http://onlinelibrary.wiley.com/doi/10.1002/cyto.b.21338/abstract

Schematics created with BioRender.com

Vaccinex Selected References, Neurology

1. Smith ES, Jonason A, Reilly C, Veeraraghavan J, Fisher T, Doherty M, Klimatcheva E, Mallow C, Cornelius C, Leonard JE, Marchi N, Janigro D, Argaw AT, Pham T, Seils J, Bussler H, Torno S, Kirk R, Howell A, Evans EE, Paris M, Bowers WJ, John G, Zauderer M. **SEMA4D compromises blood-brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease**. Neurobiol Dis. 2014 Oct 18;73C:254-268. doi: 10.1016/j.nbd.2014.10.008. http://www.sciencedirect.com/science/article/pii/S0969996114003015
2. Southwell AL, Franciosi S, Villanueva EB, Xie Y, Winter LA, Veeraraghavan J, Jonason A, Felczak B, Zhang W, Kovalik V, Waltl S, Hall G, Pouladi MA, Smith ES, Bowers WJ, Zauderer M, Hayden MR. **Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease**. Neurobiol Dis. 2015 Feb 3; 76:46–56. http://www.sciencedirect.com/science/article/pii/S0969996115000145
3. LaGanke, C., L. Samkoff, K. Edwards, L. Jung Henson, P. Repovic, S. Lynch, L. Stone, D. Mattson, A. Galluzzi, T. L. Fisher, C. Reilly, L. A. Winter, J. E. Leonard, and M. Zauderer. 2017. **Safety/tolerability of the anti-semaphorin 4D Antibody VX15/2503 in a randomized phase 1 trial**. Neurol Neuroimmunol Neuroinflamm 4: e367. https://www.ncbi.nlm.nih.gov/pubmed/28642891
4. Leonard JE, Fisher TL2 Winter LA, Cornelius CA, Reilly C, Smith ES, Zauderer M. **Nonclinical Safety Evaluation of VX15/2503; a Humanized IgG4 Anti-SEMA4D Antibody**. Mol Cancer Ther. 2015 Feb 5 http://www.ncbi.nlm.nih.gov/pubmed/25657333
5. Zauderer M, Fisher TL, Mishra V, Leonard JE, Reader A, Mallow C, Balch L, Howell A, Smith ES, and Evans EE. **SEMA4D upregulation signals neuronal stress and triggers reactive transformation of astrocytes**. *In preparation*
6. Mao Y, Evans EE, Mishra V, Balch L, Eberhardt A, Zauderer M, Gold WA. **Anti-Semaphorin 4D Rescues Motor, Cognitive, and Respiratory Phenotypes in a Rett Syndrome Mouse Model.** Int J Mol Sci. 2021 Aug 31;22(17):9465. doi: 10.3390/ijms22179465. https://www.mdpi.com/1422-0067/22/17/9465
7. Feigin AS, Evans EE , Fisher TL, Leonard JE, Reader A, Wittes J, Oakes D, Smith ES, Zauderer M, and the Huntington Study Group SIGNAL investigators. **Safety and efficacy of pepinemab antibody blockade of SEMA4D in patients with early Huntington's Disease: a randomized, placebo-controlled, multicenter, Phase 2 clinical trial (SIGNAL).** *In preparation*
8. Fisher TL, Reilly CA, Winter LA, Pandina T, Jonason A, Scrivens M, Balch L, Bussler H, Torno S, Seils J, Mueller L, Huang H, Klimatcheva E, Howell A, Kirk R, Evans E, Paris M, Leonard JE, Smith ES, Zauderer M. **Generation and preclinical characterization of an antibody specific for SEMA4D**. Mabs. 2015 Oct 20. http://www.tandfonline.com/doi/abs/10.1080/19420862.2015.1102813

Schematics created with BioRender.com

KEYNOTE B84 Site Map

Total of 18 sites planned



San Francisco, CA
UCSF Medical Center at Mission Bay
Alain Algazi

Fresno, CA
California Cancer Associates for Research and Excellence
Steven Hager

Harvey, IL
Primary Health Associates
Mark Kozloff

St Louis, MO
Siteman Cancer Center - Washington University Medical Campus
Douglas Adkins

Springdale, AR
Highlands Oncology Group
Joseph Beck

Louisville, KY
Norton Cancer Center
Jaspreet Grewal

Canton, OH
Gabrail Cancer Research Center
Nashat Gabrail

Rochester, NY
University of Rochester
Megan Baumgart

New Haven, CT
Yale Cancer Center
Barbara Burtness

Lake Success, NY
Northwell Health - Centers for Advanced Medicine
Nagashree Seetharamu

Pittsburgh, PA
Allegheny General Hospital
Larisa Greenberg

Bethesda, MD
American Oncology Partners of Maryland
Mark Goldstein

Asheville, NC
Messino Cancer Centers
Christopher Chay

Fairfax, VA
Virginia Cancer Specialists
Alexander Spira

Atlanta, GA
Emory Saint Joseph's Hospital
Conor Steuer

Orlando, FL
AdventHealth Orlando
Tarek Mekhail

Celebration, FL
AdventHealth Celebration
George Simon

Baton Rouge, LA
Hematology/Oncology Clinic
Michael Castine

San Antonio, TX
University of Texas Health Science Center at San Antonio
John Sarantopoulos

Signal-AD Site Map